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ABSTRAK 
Makroprolaktinemia di kalangan pesakit hiperprolaktinemia (HyperPRL) di Hospital 
Universiti Sains Malaysia (HUSM) 
 
Latarbelakang kajian : HyperPRL adalah gangguan hipotalamus- pituitari yang paling 
kerap dihadapi dalam endokrinologi. Makroprolaktinemia  merupakan penyebab yang 
tidak merbahaya bagi hyperPRL. Makroprolaktin adalah bentuk tidak aktif PRL yang 
terdiri daripada prolaktin (PRL) monomer dan antibodi Immunoglobulin G. Penularan 
makroprolaktinemia semakin meningkat dalam amalan endokrinologi. Adalah penting 
untuk membezakan di antara makroprolaktinemia dan hyperPRL kerana 
makroprolaktinemia tidak memerlukan rawatan. Selain itu, gejala klinikal tidak dapat 
membezakan antara kedua - dua keadaan.  
Tujuan: Untuk mengenalpasti prevalens makroprolaktinemia dan ciri-ciri klinikal yang 
ketara berkaitan dengan makroprolaktinemia di kalangan pesakit hyperPRL di HUSM. 
Rekabentuk kajian: Satu kajian hirisan lintang telah dijalankan pada tahun 2013 yang 
melibatkan pesakit yang didiagnosis sebagai hyperPRL di HUSM 2011 to 2013. Serum 
daripada pesakit ini diukur untuk PRL dengan menggunakan cobas e411 (prinsip 
sandwich) dan serum yang sama dirawat dengan polietilena glikol (PEG) 8000 untuk 
membezakan hyperPRL benar dan makroprolaktinemia. Pemulihan PRL kurang dari 
40% menunjukkan kehadiran makroprolaktin. 
Keputusan kajian: Sejumlah 133 pesakit hyperPRL , 120 (90 %) wanita dan 13 (9.8%) 
lelaki berusia di antara 18 hingga 68 tahun dengan min (SD) umur 34.37 tahun (11.75) 
telah dimasukkan dalam kajian ini.  Sembilan pesakit (semua perempuan) didapati 
xvi 
mempunyai makroprolaktinemia [kelaziman = 6.8 % (95 % CI: 2.4 %, 11.1 %)]. Tiada 
hubungan yang signifikan di antara tanda-tanda klinikal dan diagnosis 
makroprolaktinemia dalam kajian ini.  
Kesimpulan: Penularan makroprolaktinemia dikesan dengan menggunakan PEG 8000 
di kalangan pesakit yang didiagnosis sebagai hyperPRL adalah rendah. Saringan untuk 
makroprolaktin menggunakan PEG 8000 menunjukkan bahawa kebanyakan pesakit 
yang datang dengan hyperPRL di HUSM adalah hyperPRL benar. Oleh itu, tanda-tanda 
klinikal tidak dapat membezakan antara hyperPRL dan makroprolaktinemia. 
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ABSTRACT 
Macroprolactinemia among Hyperprolactinemia (HyperPRL) Patients in Hospital 
Universiti Sains Malaysia (HUSM) 
 
Background: HyperPRL is the most common hypothalamic-pituitary disorder 
encountered in clinical endocrinology. Macroprolactinemia is a known benign cause of 
hyperPRL.  Macroprolactin is a non-bioactive form of PRL, composed of monomeric 
PRL and Immunoglobulin G antibodies. The prevalence of macroprolactinemia is 
increasing in endocrinology practice. It is important to differentiate between 
macroprolactinemia and hyperPRL as macroprolactinemia does not require any 
treatment. However the clinical symptoms are could not differentiate between these two 
conditions.  
Aim: To determine the prevalence of macroprolactinemia and significant clinical 
features associated with macroprolactinemia among hyperPRL patient in HUSM. 
Design: A cross sectional study was conducted in 2013 involving patients diagnosed as 
hyperPRL in HUSM from 2011 to 2013. Serum from these patient were measured for 
PRL using cobas e411 (sandwich principle) and the same serum were treated with 
polyethylene glycol (PEG) 8000 to differentiate true hyperPRL and 
macroprolactinemia. PRL recovery of less than 40% indicates of presence 
macroprolactin.  
Results: A total of 133 hyperPRL patients, 120 (90%) female and 13 (9.8%) male aged 
between 18 to 68 years old with mean (SD) age of 34.37 (11.75) years old were 
included in this study. Nine patients (all female) were found to have 
xviii 
macroprolactinemia [prevalence=6.8% (95% CI: 2.4%, 11.1%)]. There were no 
significant association between clinical symptoms and diagnosis of macroprolactinemia 
in this study. 
Conclusion: The prevalence of macroprolactinemia detected using PEG 8000 among 
patients diagnosed as hyperPRL was low. Screening for macroprolactin using PEG 
8000 showed that majority of patients presented with hyperPRL in HUSM were true 
hyperPRL. Clinical symptoms alone therefore, could not distinguish between hyperPRL 
and macroprolactinemia. 
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CHAPTER 1: INTRODUCTION 
1. Introduction 
Prolactin (PRL) is a hormone secreted by specialized cell within the 
adenohypophysis. The primary role of PRL is to stimulate and sustain lactation during 
postpartum period. PRL has many other effects including maintenance of immune 
system and in ovarian steroidogenesis. PRL also known as lactogen, lactotropin, 
luteotropin, mammotropin or galactopoietic, lactation, lactogenic or luteotropic 
hormone (Tietz, 2006). 
PRL is synthesized as a prehormone with a molecular weight of 26 kDa. PRL 
contain 199 amino acids and has three intramolecular disulphide bridges. When the 
prePRL is cleaved, the resulting polypeptide has a molecular weight of 23 kDa (60 to 
90%). This monomeric form accounts for the majority of total PRL. Serum also 
contains a 48-56 kDa (15 to 30%) form that is termed as big PRL and another isoform  
with a molecular weight of more than l00 kDa ( zero to10%), which is termed as big big 
PRL (Tietz, 2006). The PRL polypeptide is arranged in a single chain of amino acids 
with three highly conserved intramolecular disulfide bonds between six cysteine 
residues. According to nuclear magnetic resonance spectroscopy, PRL folds into four 
antiparallel alpha helices, similar to the tertiary structure of growth hormone (GH) and 
other close relatives (Keeler et al., 2003). Figure 1.1 below shows illustration of PRL 
proteins as they exist in the serum as three forms: monomeric 23 kDa PRL (>95%), ―big 
PRL,‖ consisting of PRL aggregates and ―big big PRL,‖ or macroprolactin, consisting 
of PRL bound to immunoglobulin G (IgG). Red hatching indicates the relative locations 
of the three disulfide bonds. A single N-glycosylation site has been identified on human 
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PRL at codon 31. Two putative phosphorylation sites (not depicted) have been proposed 
at serines 163 and 194 (Keeler et al., 2003). 
  
 
              
Figure 1.1: Schematic illustration of prolactin proteins. (Keeler et al., 2003) 
 
The monomeric form is considered as the most bioactive form that found in the 
circulation and demonstrate the greatest response to thyrotrophin releasing hormone 
(TRH), the hypothalamic releasing factor that stimulates the pituitary to release PRL 
(Tietz, 2006). 
Hyperprolactinemia (HyperPRL) is the most common hypothalamic-pituitary 
disorder encountered in clinical endocrinology. The clinical syndromes of hyperPRL are 
galactorrhea, oligomenorrhea or amenorrhea and infertility in women and reduced 
libido, oligospermia or impotence or both and also galactorrhea in men. HyperPRL has 
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an estimated prevalence of 15% in women with secondary amenorrhea, a condition that 
affects at least three per cent of women of reproductive age (Gibney et al., 2005c). 
In general, big big PRL also known as macroprolactin is a non-bioactive PRL 
isoform usually composed of a PRL monomer and an IgG molecule (Kavanagh‐Wright 
et al., 2009; Richa et al., 2010). It is have a prolonged clearance rate similar to that of 
immunoglobulins. This isoform is clinically non-reactive but it interferes with 
immunological assays used for the detection of PRL (Richa et al., 2010). When the 
serum of a patient with hyperPRL contains mostly macroprolactin the condition is 
termed macroprolactinemia. Because some of the laboratories fail to screen 
hyperprolactinemic sera for macroprolactinemia this may lead to misdiagnosis and 
unnecessary medical and surgical intervention (Beltran et al., 2008) or delayed 
diagnosis and inappropriate treatment.(Olukoga et al., 1999; Suliman et al., 2003; 
Gibney et al., 2005a). 
Screening of hyperprolactinemic sera for the presence of misleading 
concentrations of macroprolactinemia is readily performed in biochemistry laboratories 
although the procedures have not been automated. The most widely employed method is 
to treat the hyperprolactinemic sera with polyethylene glycol (PEG) which precipitates 
out high-molecular weight constituents including immunoglobulins. Re-assay of the 
sera for PRL will then identify those sera which yield values within the relevant normal 
range indicative of macroprolactinemia and not true hyperPRL (Joseph McKenna, 
2009).  
There are few methods available to remove macroprolactin namely, gel filtration 
chromatography (GFC), PEG, protein A (PA), protein G (PG), anti-human IgG (anti-
hIgG), and ultrafiltration (UF). These methods deplete macroprolactin from sera before 
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immunoassay. Among all the methods available, PEG is the suitable and practical 
method (Kavanagh et al., 2006). Generally PEG precipitation is used to differentiate 
macroprolactinemia from true hyperPRL. This method is simple, cheap and rapid for 
the detection of macroprolactinemia (Leslie et al., 2001). This method has been 
extensively validated against GFC and has obtained good correlation (Vieira et al., 
1998; Fahie-Wilson, 1999; Olukoga et al., 1999).  
GFC technique is robust and reproducible. It is often considered as the gold 
standard. There are four main disadvantages. First, with a low affinity antibody complex 
there exists the potential for dissociation of PRL from the autoantibody during the 
lengthy gel filtration run, thereby this leads to an underestimation of the macroprolactin 
content in serum. In practice, dissociation to any appreciable extent does not take place, 
indicating that macroprolactin is probably a high affinity complex. Secondly, there is 
considerable inherent cumulative imprecision associated with measuring the levels of 
PRL and macroprolactin in 30 to 40 discrete fractions to obtain an estimate of the 
percentage of macroprolactin present. Third, procedural loss of PRL immunoreactive 
material through adsorption or denaturation during the gel filtration runs if selective. It 
could be a disproportionate loss of either PRL or macroprolactin, which would lead to 
either under- or overestimation of the individual isoforms present. Fourth, the labour-
intensive nature and expense of GFC usually preclude its widespread use in all except 
for research laboratories (Gibney et al., 2005c). 
5 
CHAPTER 2: LITERATURE REVIEW 
2. Literature Review 
2.1. Prolactin 
2.1.1. Gene, primary structure and species specificity 
PRL belongs to the somatotropin/PRL family, a large family of proteins that 
includes GH, placental lactogens (PL), PRL-like and PRL-related proteins, proliferins 
and proliferin-related proteins. The human PRL gene is located on chromosome 6p22.2-
p21.3 and consists of five coding exons, one noncoding exon and four introns (Truong 
et al., 1984). It is believed that PRL, GH and PL arose from duplication of a common 
ancestral gene  400 million years ago (Niall et al., 1971; Cooke et al., 1981).The 
divergence of the PRL and GH lineages occurred; 400 million years ago as quoted by 
Cooke et al (1981).  
In the human genome, a single gene was found on chromosome six that  
encoded PRL (Owerbach et al., 1981). The PRL gene is 10 kilobase in size and is 
composed of five exons and four introns (Cooke et al., 1981; Truong et al., 1984). 
Transcription of the PRL gene is regulated by two independent promoter regions. The 
proximal 5,000 base pairs (bp) region directs pituitary-specific expression (Berwaer et 
al., 1991), while a more upstream promoter region is responsible for extrapituitary 
expression (Berwaer et al., 1994). The human PRL complementary DNA is 914 
nucleotides long and contains a 681-nucleotide open reading frame encoding the PRL 
prehormone (pre-PRL) of 227 amino acids. During PRL processing, the 28-amino acid 
signal peptide is proteolytically cleaved (Shome and Parlow, 1977), resulting in a 
mature human PRL. (Sinha, 1995). Figure 2.1 below shows schematic diagram of the 
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human PRL 5‘ gene regulatory region, gene and messenger RNA transcript. The PRL 
gene consists of five exons, designated by the numbers [1e5]. The region from e5800 bp 
to zero indicates the region known to regulate pituitary PRL synthesis whereas the 
region from e8789 to e5800 is referred to as the ―superdistal‖ or ―extrapituitary‖ 
promoter region. Thirteen Pit1-binding sites are present in the regulatory region. A 
single degenerate estrogen response element has been identified at e1189 bp. The 
extrapituitary PRL mRNA is ~150 bp longer than the pituitary transcript, and has a 
different 5‘untranslated region, but transcription from either promoter produces 
identical protein coding sequences (Melmed, 2010). 
 The PRL molecule is arranged in a single chain of amino acids with three 
intramolecular disulfide bonds between six cysteine residues (Cys
4
-Cys
11
, Cys
58
-Cys
174
, 
and Cys
191
-Cys
199 
in humans) (Cooke et al., 1981) as shown in Figure 2.2. The sequence 
homology can vary from the striking 97% among primates to as low as 56% between 
primates and rodents (Sinha, 1995). In humans (Shome and Parlow, 1977). PRL 
consists of 199 amino acids with a molecular mass of 23 kDa whereas in rats (Cooke et 
al., 1980)  pituitary PRL consists of only 197 amino acids.  
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Figure 2.1: Schematic diagram of the human prolactin 5‘ gene regulatory region, gene 
and messenger RNA transcript (Melmed, 2010) 
 
           
Figure 2.2: Amino acid sequence of prolactin. Three cysteine disulfide bands are 
located within the molecule (C. Matthew Peterson, 2004) 
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2.1.2. Secondary and tertiary structure of prolactin 
Studies on the secondary structure of PRL have shown that 50% of the amino 
acids chain is arranged in α-helices, while the rest of it forms loops (Bewley and Li, 
1972). The tertiary structure of PRL was predicted by homology modelling approach 
(Goffin et al., 1995), based on the structural similarities between PRL and other helix 
bundle proteins, especially GH (Abdel-Meguid et al., 1987; De Vos et al., 1992). 
According to the current three-dimensional model, PRL contains four long α-helices 
arranged in antiparallel fashion (Abdel-Meguid et al., 1987; De Vos et al., 1992). 
 
2.1.3. Prolactin variants 
Although the major form of PRL found in the pituitary gland is 23 kDa, variants 
of PRL have been characterized in many mammals, including humans. PRL variants 
can be as a result of alternative splicing of the primary transcript, proteolytic cleavage 
and other posttranslational modifications of the amino acid chain (Freeman et al., 2000). 
The majority of PRL variants are of posttranslational processing of the mature 
molecule in the anterior pituitary gland or the plasma. These include dimerization and 
polymerization, phosphorylation into 14,16 and 22 kDa forms, glycosylation, sulfation, 
and deamidation (Freeman et al., 2000).  
 
2.2. Prolactin synthesis and secretion patterns 
PRL consists of 199 amino acids with three intramolecular disulfide bonds. It is 
synthesized as a prehormone with a molecular weight of 26 kDa (Sinha, 1995). When 
9 
the prehormone is proteolytically cleaved, the resulting mature polypeptide has a 
molecular weight of 23 kDa, and this monomeric form accounts for the majority of total 
PRL in the serum of normal subjects and most patients with hyperPRL (Freeman et al., 
2000).  
PRL is secreted episodically by the anterior pituitary and is primarily under 
tonic inhibitory control by hypothalamic dopamine traversing the portal venous system 
to impinge on lactotroph D2 receptors (Freeman et al., 2000; Melmed, 2003). There is 
an innate pulsatility to pituitary PRL secretion with an interpulse interval of about eight 
minutes, as determined by studies of media obtained from primate pituitaries cultured in 
vitro (Stewart et al., 1985). 
Figure 2.3 shows the nature of PRL secretion throughout the day in a single 
individual superimposed upon the range from five normal individuals. The pattern 
shows the episodic nature of secretion and the nocturnal rise (Melmed, 2010). 
 
 
Figure 2.3: Nature of prolactin secretion (Melmed, 2010).  
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When plasma is sampled from normal individuals in whom hypothalamic 
function is superimposed upon this innate pulsatility, it becomes apparent that there are 
four to14 secretory episodes per day. Using cluster analysis, 13 to 14 peaks per day in 
young subjects were found with a peak duration of 67 to 76 minutes, a mean peak 
amplitude of three to four ng/ml and an interpulse interval of 93 to 95 min (Veldhuis 
and Johnson, 1988). An elevation of basal PRL levels in hypothalamic tumour is due to 
an increase in pulse amplitude and not pulse frequency (Samuels et al., 1991). 
 
2.2.1. Sleep with prolactin 
An increase in the amplitude of the PRL secretory pulses begins about 60 to 90 
minutes after the onset of sleep; the secretory pulses increase with non-rapid eye 
movement sleep resulting in highest concentration and fall prior to the next period of 
rapid eye movement sleep (Parker et al., 1974). When subjects are kept awake to 
reverse the sleep-waking cycle, PRL levels do not rise until sleep begins (Sassin et al., 
1973). Thus, the diurnal variation of PRL secretion is not an inherent rhythm but 
depends on the occurrence of sleep. Interestingly, the diurnal variation of PRL with the 
sleep-induced rise persists despite other powerful physiologic influences such as 
breastfeeding (Stern and Reichlin, 1990). 
 
2.2.2. Meals with prolactin 
There is an increase in circulating PRL levels of 50 to 100% within 30 minutes 
of meals that is due to the amino acids generated from the protein component of the 
meals, phenylalanine, tyrosine and glutamic acid being the most potent in this regard 
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(Carlson et al., 1989). Carlson et al. (1989) have provided evidence that this stimulatory 
action of these amino acids is centrally mediated by showing that large neutral amino 
acids such as valine inhibit the transport of phenylalanine across the blood-brain barrier 
and blunt the stimulatory action of this amino acid. 
 
2.2.3. Pregnancy with prolactin  
Physiological levels of PRL are higher during pregnancy and lactation than 
otherwise and the mean serum levels are higher in women than in men (Delitala, 1998).  
 
2.2.4. Other factors 
Factors inducing PRL synthesis and secretion include estrogen, thyrotropin-
releasing hormone, epidermal growth factor, and dopamine receptor antagonists 
(Melmed et al., 2011). 
 
2.3. Metabolic clearance and production rates of prolactin 
Using a labelled PRL method, the metabolic clearance rate has been found to be 
46  4 and 40  6 ml/min/m2 and the calculated production rates using the labelled PRL 
method were 200  63 and 536  218 mg/day/m2 in two studies (Cooper et al., 1979; 
Sievertsen et al., 1980) . Studies in patients with chronic renal failure have shown the 
metabolic clearance rate to be reduced by 33% (Sievertsen et al., 1980); increased 
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uptake by the liver has been found in nephrectomised rabbits (Falconer and Vacek, 
1983). 
 
2.4. Regulation of prolactin 
Similar to other anterior pituitary hormones, PRL is under dual regulation by 
hypothalamic hormones delivered through the hypothalamic–pituitary portal circulation. 
Under most conditions the predominant signal is inhibitory, preventing PRL release, 
and is mediated by the neurotransmitter dopamine. The stimulatory signal is mediated 
by the hypothalamic hormone thyrotropin-releasing hormone (TRH). Increased anterior 
pituitary hormone production can occur from a PRL-producing adenoma or from 
inflammation (hypophysitis). However, conditions that result in impaired dopamine 
delivery or enhanced TRH signalling, or both, will also result in increased PRL release. 
In general, medications result in increased PRL production through their anti-
dopaminergic properties. Chest-wall injury and breast stimulation serve as peripheral 
triggers of autonomic control, which impinge on central neurogenic pathways that 
attenuate dopamine release into the hypophyseal portal circulation. Furthermore, the 
amount cleared by the kidneys influences the concentration of PRL in the blood. 
(Vallette-Kasic et al., 2002a; Serri et al., 2003) (Figure 2.4) 
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Figure 2.4:  Prolactin regulation.(Serri et al., 2003)  
 
2.5. Physiological action of prolactin 
PRL helps in controls of the initiation and maintenance of lactation. However, it 
needs estrogens, progestins, corticosteroids, thyroid hormone and insulin in order for an 
appropriate expression of PRL action. PRL induces ductal growth, development of the 
breast lobular alveolar system and the synthesis of specific milk proteins, including 
casein and γ-lactalbumin. PRL also has effects on the immune system and important in 
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the control of osmolality and various metabolic events, including the metabolism of 
subcutaneous fat, carbohydrate metabolism, calcium and vitamin D metabolism, fetal 
lung development and steroidogenesis (Tietz, 2006).  
 
2.6. Hyperprolactinemia 
HyperPRL is a condition of elevated PRL levels in blood which could be 
physiological, pathological, or idiopathic in origin. Similarly elevated PRL levels could 
be associated with severe clinical manifestations on one side of the spectrum or be 
completely asymptomatic on the other side (Majumdar and Mangal, 2013). 
HyperPRL has an estimated prevalence of 15% in women with secondary 
amenorrhoea (Bergh et al., 1977) a condition that affects at least three per cent of 
women of reproductive age (Münster et al., 1992). 
Physiological conditions associated with an increased PRL release include 
pregnancy, puerperium, nursing, stress, pain, physical exercises, coitus, nocturnal sleep, 
high-protein meals and late follicular and luteal phase of menstrual cycle (Kasum et al., 
2012). 
Whereas pathological hyperPRL or true hyperPRL can be results from a 
lactotroph adenoma, conditions that increase TRH, empty sella syndrome, intracranial 
tumours compressing the pituitary stalk or hypothalamus, dopamine receptor D2 
antagonist and PRL stimulative drugs, repetitive mechanical stimulation of breast, chest 
wall trauma, hepatorenal disease and primary hypothyroidism, or conditions in which 
reduced clearance of PRL occurs, such as renal failure (Gibney et al., 2005c; Kasum et 
al., 2012). Usually pathological hyperPRL is caused by biologically active PRL. It is 
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associated with suppression of gonadotrophin secretion and gonadal activity (Thorner, 
1977).  
Idiopathic hyperprolactinemia (IH) can be defined as the presence of elevated 
serum PRL levels in a patient in the absence of demonstrable pituitary or central 
nervous system disease and of any other recognized cause of increased PRL secretion 
(Martin et al., 1985). The major cause of IH is due to macroprolactinemia, in which 
most circulating PRL forms large protein complexes (more than 150 kDa). The patients 
with macroprolactinemia have non-pathologic gonadotropin and gonadal activity and 
clinically characterized by the lack of hyperPRL-related symptoms such as amenorrhea 
and galactorrhea (Fraser et al., 1989; Hattori et al., 1992a; Hattori, 2003). 
The clinical manifestations of hyperPRL are relatively few and easy to 
recognize. Typical symptoms of hyperPRL can be seen in premenopausal women and in 
men, but not in postmenopausal women. In premenopausal women causes 
hypogonadism, manifested by infertility, oligomenorrhoea, or amenorrhoea and less 
often by galactorrhoea. Excluding pregnancy, hyperPRL accounts for approximately 10 
to 20% of cases of amenorrhoea. The mechanism appears to involve inhibition of 
luteinizing hormone (LH) and perhaps follicle-stimulating hormone (FSH) secretion, 
via inhibition of the release of gonadotropin-releasing hormone (GnRH). As a result, 
serum gonadotropin concentrations are not supranormal, typical of other causes of 
secondary hypogonadism (Snyder et al., 2006). 
The symptoms of hypogonadism due to hyperPRL in premenopausal women 
correlate with the magnitude of the hyperPRL. Postmenopausal women, by definition, 
are already hypogonadal, and hyperPRL does not change that situation. Galactorrhoea is 
rarely seen in postmenopausal women because postmenopausal women are markedly 
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hypoestrogenemic. HyperPRL in these women is recognized only in the relatively 
unusual situation when a lactotroph adenoma becomes so large as to cause headaches or 
visual impairment. HyperPRL also causes hypogonadotropic hypogonadism in men, 
which is manifest by reduced libido, impotence, infertility, gynecomastia, or rarely 
galactorrhoea (Snyder et al., 2006).  
 
2.6.1. Macroprolactinemia 
Macroprolactinemia is characterized by presence of macroprolactin as the main 
molecular form of PRL in sera and the lack of symptoms. Macroprolactin has a 
molecular mass of more than 150 kDa, usually contributes a small, though variable 
amount to circulating levels (Suh and Frantz, 1974; Smith and Norman, 1990). Majority 
of cases, macroprolactin consists of an antigen–antibody complex of monomeric PRL 
and IgG (Hattori et al., 1992b; Hattori and Inagaki, 1997b; De Schepper et al., 2003; 
Kavanagh‐Wright et al., 2009; Hattori et al., 2010). 
 
2.6.1.1. Prevalence of macroprolactinemia in the general population 
Study in healthy Japanese adult done in 1990 found that 0.4% (40 subjects) had 
hyperPRL. A quarter of these hyperprolactinaemic subjects were macroprolactinemic, 
eight subjects were female (Ichihara and Miyai, 1990). None of these 10 subjects had 
symptoms or signs of endocrine dysfunction. However other study done by Bjoro et al 
in 1995 identified only one female patient with macroprolactinemia. These findings 
suggest that macroprolactinemia probably exists in the general population at a 
prevalence of 0.2% in women, but only 0.02% in men. 
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Another study by Hatorri et al (2009) suggests shows that macroprolactinemia is 
more common, with a prevalence of 3.68% and no difference in prevalence between 
males and females.  
 
2.6.1.2. Prevalence in the hyperprolactinemia patients 
The prevalence of macroprolactinemia among hyperPRL patients varies 
depending upon the assay used to measure PRL and the subgroup of patients selected 
for the studies. Few studies showed variation in  prevalence of macroprolactinemia in 
hyperprolactinemic populations between 15 and 46% (Bjoro et al., 1995; Vieira et al., 
1998; Olukoga and Kane, 1999; Leslie et al., 2001; Smith et al., 2002b). The lowest 
incidence which was 15% (Olukoga and Kane, 1999) and highest incidence which were 
46% (Hauache et al., 2002) as shown in Table 2.1. 
A study regarding screening for macroprolactinemia among hyperPRL done in 
UK found that prevalence of macroprolactinemia reported varied from 15 to 46% 
(Gibney et al., 2005c).  Prevalence for macroprolactinemia in UK and US were 
estimated about five to 15% of all cases of hyperPRL (Joseph McKenna, 2009). 
Macroprolactinemia has been most frequently described and investigated in women 
because serum PRL is more frequently measured in females as one of the investigation 
for infertility (Radavelli-Bagatini et al., 2013). 
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Table 2.1:  Prevalence of macroprolactinemia in studies in which all 
hyperprolactinaemic samples were screened for macroprolactin 
Reference Country  N Threshold(mIU/L) Prevalence (%) 
Bjoro et al. 1995 Norway  605 1000 25 
Fahie-Wilson and 
Soule 1997 
England 69 700 25 
Viera et al. 1998 Brazil 1220 540 36 
Olukoga and Kane 
1999 
UK 188 430 15 
Leslie et al. 2001 UK 1225 700 26 
Smith et al. 2002 Ireland  300 700 24 
Hauache et al. 2002 Brazil  113 620 46 
Strachan et al. 2003 UK 273 700 21 
Source : Clinical relevance of macroprolactin from Clinical endocrinology N, number 
of subjects with hyperprolactinemia; Threshold, level of total PRL above which 
screening for macroprolactin was undertaken (Gibney et al., 2005c). 
 
2.6.1.3. Macroprolactinemia in men  
HyperPRL in men may be associated with reduced testosterone, decreased 
libido, galactorrhoea and impotence. These symptoms are at least partially due to 
suppression of the hypothalamic–pituitary–gonadal axis, although a direct effect of PRL 
may also occur. Few reports exist concerning macroprolactinemia in male subjects, but 
those that exist suggest reduced in vivo bioactivity (Gibney et al., 2005c). A study in 
1996 reported six male subjects who were evaluated for sexual dysfunction and found to 
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have elevated PRL levels but normal testosterone levels and no evidence of any 
abnormality of the pituitary on MRI scanning (Guay et al., 1996). When submitted to 
GFC, serum PRL from these subjects proved to be predominantly macroprolactin. A 
surprising feature of this study was that six subjects with macroprolactinemia were 
identified from a total of 326 consecutive patients with impotence. This represents a 
prevalence of two per cent or approximately 100 times that expected for men in the 
general population. 
The same group subsequently reported on two men with pituitary 
macroadenomas in whom the majority of circulating PRL was macroprolactin (Tritos et 
al., 1998). These men had normal sexual function and normal tests of nocturnal penile 
tumescence and rigidity. However, both had extremely high levels of circulating PRL (> 
10 000 mU/l) and there was evidence that both were tumours secreted PRL. These 
findings can be explained by the concept that antibodies directed against PRL may have 
reduced the bioavailability of PRL and thus producing the clinical manifestations of 
hyperPRL.  
 
2.6.1.4. Macroprolactinemia in children and adolescent 
In children hyperPRL has been described infrequently. This may reflect the less 
common measurement of PRL in children. However, there has been a series of five 
children with macroprolactinemia reported. Two of the children had three CT or MRI 
scans each in search of pituitary lesions with abnormalities detected. Fideleff et al 
(2000) reported five patients (one male and four females) aged 11 to 18 years with 
asymptomatic hyperPRL who underwent repeated evaluations over a period of three 
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months to eight years. In all of these cases increased levels of either macroprolactin or 
big PRL were identified (Fideleff et al., 2000). 
A study in Turkey involving six children and adolescent with 
macroprolactinemia revealed that one patient was asymptomatic and the other five had 
non-specific symptoms (headache, menstrual disturbance, short stature, increased hair 
growth or early puberty). The researcher concluded that macroprolactinemia should be 
taken into consideration in the differential diagnosis of hyperPRL in childhood although 
the patient presented with or without relevant clinical symptoms (Tutunculer et al., 
2006). 
 
2.6.1.5. Macroprolactinemia in elderly 
There has been limited number of published study available on 
macroprolactinemia among elderly. Only one study had described the prevalence of 
macroprolactinemia among elderly. The study which involved a large number of 
hospital worker (1330 worker) reported the prevalence of macroprolactinemia among 
elderly age 60 to 73 years old was 9.1%. The prevalence of macroprolactinemia in the 
older age group was higher compared to those in lower age group (2.8% in those aged 
18 to 39 years old and 4.8% in those aged 40 to 59 years old). The study also observed a 
statistically significant difference in proportion of patients with macroprolactinemia 
between those aged 60 to 73 years old and those aged 18 to 39 years old. 
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2.6.1.6. Macroprolactinemia in pregnancy 
During pregnancy, there is a great increment of serum PRL level occurs, and the 
presence of big big PRL has been reported in a range of eight to 38% of total PRL (Suh 
and Frantz, 1974; Farkouh et al., 1979; Pansini et al., 1985). Jackson et al. reported two 
women with persistent macroprolactinemia who became pregnant in spite of hyperPRL, 
and macroprolactin was the predominant isoform during pregnancy (Jackson et al., 
1989).  
 
2.6.1.7. Clinical features of macroprolactinemia 
There are two mechanisms that may be responsible for macroprolactin to have 
minimal bioactivity in vivo. Firstly the high molecular mass complex is likely to be 
restricted to the intravascular compartment by virtue of its size. Secondly steric 
hindrance by the bound anti-PRL auto-antibody may prevent binding of PRL to its 
receptor (Hattori et al., 2007). 
The evidence of minimal bioactivity suggests that macroprolactin is unlikely to 
be a cause of symptoms mirroring the hyperprolactinaemic syndrome. Few studies have 
reported that patients with macroprolactinemia have lower frequency of symptoms and 
a better prognosis than other hyperprolactinemic patients. It is because of its high 
molecular mass, which makes macroprolactin confined to the vasculature and hence 
exhibits limited bioactivity in vivo. One study found a low prevalence of symptoms of 
menstrual irregularity (23.6%), galactorrhoea (1.8%), and headache (10.9%) (Hattori et 
al., 2009).These findings have been replicated in other studies (Vieira et al., 1998; 
Olukoga and Kane, 1999; Smith et al., 2002a; Vallette-Kasic et al., 2002b). 
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Gibney et al. (2005) stated that macroprolactinemic patients could not be 
differentiated from true hyperprolactinemic patients on the basis of clinical features 
alone. Although oligomenorrhoea or amenorrhoea and galactorrhoea were more 
common in patients with true hyperPRL (P < 0.05), they were also frequently present in 
macroprolactinemic patient. 
Oligomenorrhoea or amenorrhoea in true hyperPRL is characterized by low 
levels of oestradiol and low or inappropriately normal concentrations of FSH and LH, 
reflecting the hypothalamic origin of the disturbance. However study in 2003 had found 
that plasma levels of oestradiol and LH proved significantly higher in 
macroprolactinemic compared with true hyperprolactinemic subjects (Suliman et al., 
2003) (Table 2.2). 
It is likely that the association of the relatively common symptoms of 
galactorrhoea and oligomenorrhoea and the biochemical finding of macroprolactinemia 
were observed in this and other studies (Olukoga et al., 1999; Leslie et al., 2001; 
Vallette-Kasic et al., 2002a; Fahie-Wilson et al., 2005; Gibney et al., 2005c) was 
coincidental. A study done by Olukoga (2002) had suggested that macroprolactin can be 
responsible for some patients with macroprolactinemia to have symptoms consistent 
with hyperPRL, for which no other cause can be found. 
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Table 2.2: Clinical and laboratory data in true hyperprolactinemic and 
macroprolactinemic groups
a
 
Characteristics Hyperprolactinemia  
(n= 100) 
Macroprolactinemia 
(n=32) 
Age (yr) 35 (19–69) 29 (18–59) 
Total PRL (mIU/liter) 1315 (514–6775) 1145 (517–3390) 
PRL after PEG precipitation 
(mIU/liter) 
992 (393–5776) 240 (99–384) 
FSH, IU/L 5.7 (0.5) 7.1 (2.1) 
LH, IU/L 5.3 (0.5) 10.1(2.4)
 
Estradiol pmol/L 162 (33) 284 (48)
 
Clinical features   
     Oligomenorrhoea or        
     amenorrhoea   
73% 59%
 
     Galactorrhoea 54% 22%
 
     Infertility 7% 22% 
     Headache 7% 5% 
a 
Data are mean (SE). Reference intervals: prolactin, 78–564 mIU/L; prolactin after PEG 
precipitation, 70–403 mIU/L; FSH, 2–25 IU/L; LH, 2–50 IU/L; estradiol, 110–1470 
pmol/L. 
Source : Frequent Misdiagnosis and Mismanagement of Hyperprolactinemic Patients 
before the Introduction of Macroprolactin Screening: Application of a New Strict 
Laboratory Definition of Macroprolactinemia (Suliman et al., 2003). 
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Suliman et al. (2003) pointed out that the presence of a substantial proportion of 
macroprolactin does not exclude a coincident elevated concentration of bioactive 
monomeric PRL, which could explain the appearance of symptoms in cases of 
macroprolactinemia, as in those cases reported by Olukoga and Kane (1999). 
Nevertheless, there is no doubt that symptoms of the hyperprolactinaemic syndrome are 
commonly found in clinical practice in subjects with macroprolactinemia. Gibney et al. 
(2005) reviewed the clinical features in 310 patients with macroprolactinemia from 
eight series and found that zero to 45% presented with galactorrhoea, six to 40% with 
subfertility and 15 to 80% with oligomenorrhoea or amenorrhoea. However, there was 
no convincing evidence that these symptoms were caused by macroprolactin. In the 
retrospective study of Suliman et al. (2003), the prevalence of oligomenorrhoea or 
amenorrhoea and galactorrhoea was significantly lower (57% and 29% respectively) in 
patients with macroprolactinemia relative to those with true hyperPRL (84% and 63%). 
Moreover, there have been a substantial number of reports of patients who 
presented with symptoms similar to those of the hyperprolactinemic syndrome, were 
found initially to have hyperPRL, but on follow-up and further investigation were found 
to be ovulating or had conceived spontaneously and the hyperPRL was attributable to 
macroprolactin (Carlson et al., 1992; Hattori et al., 1993; Hattori et al., 1994; Hattori, 
1996; Hattori and Inagaki, 1997a; Olukoga et al., 1999). Given that measurement of 
PRL is prompted by symptoms of the hyperprolactinemic syndrome and these 
symptoms are not specific (Gibney et al., 2005c).  
HyperPRL was found in a minority of patients who present with symptoms 
suggestive of the hyperprolactinemic syndrome and macroprolactinemia in only 14 of 
955 (1.5%). Hence, if the symptoms in these cases of macroprolactinemia are 
coincidental and do not exhibit a cause and effect relationship, a similar prevalence of 
